Check-Cap (NASDAQ:CHEK) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Check-Cap (NASDAQ:CHEK) in a research note issued to investors on Monday. The firm issued a sell rating on the medical research company’s stock.

Check-Cap Stock Down 0.5 %

Shares of Check-Cap stock traded down $0.01 on Monday, reaching $1.91. The stock had a trading volume of 7,633 shares, compared to its average volume of 116,964. The stock has a market capitalization of $11.17 million, a P/E ratio of -0.64 and a beta of 0.40. The company has a 50 day moving average price of $2.09 and a 200 day moving average price of $2.18. Check-Cap has a 1 year low of $1.78 and a 1 year high of $4.63.

Check-Cap (NASDAQ:CHEK) last released its quarterly earnings results on Wednesday, May 15th. The medical research company reported ($0.62) earnings per share (EPS) for the quarter. On average, analysts forecast that Check-Cap will post -0.68 earnings per share for the current fiscal year.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.